Top

Published in:

Open Access 01-12-2021 | Oral Cancer | Review

Fusobacterium nucleatum and oral cancer: a critical review

Authors: Emily McIlvanna, Gerard J. Linden, Stephanie G. Craig, Fionnuala T. Lundy, Jacqueline A. James

Published in: BMC Cancer | Issue 1/2021

Abstract

There is a growing level of interest in the potential role inflammation has on the initiation and progression of malignancy. Notable examples include Helicobacter pylori-mediated inflammation in gastric cancer and more recently Fusobacterium nucleatum-mediated inflammation in colorectal cancer. Fusobacterium nucleatum is a Gram-negative anaerobic bacterium that was first isolated from the oral cavity and identified as a periodontal pathogen. Biofilms on oral squamous cell carcinomas are enriched with anaerobic periodontal pathogens, including F. nucleatum, which has prompted hypotheses that this bacterium could contribute to oral cancer development. Recent studies have demonstrated that F. nucleatum can promote cancer by several mechanisms; activation of cell proliferation, promotion of cellular invasion, induction of chronic inflammation and immune evasion. This review provides an update on the association between F. nucleatum and oral carcinogenesis, and provides insights into the possible mechanisms underlying it.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin 2018;68(6):394–424, DOI: https://doi.org/10.3322/caac.21492.

Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, González-Moles MÁ, Kerr AR, et al. Oral potentially malignant disorders: a consensus report from an international seminar on nomenclature and classification, convened by the WHO collaborating Centre for Oral Cancer. Oral Dis. 2020. https://doi.org/10.1111/odi13704 Epub ahead of print.

Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580–93. https://doi.org/10.1038/bjc.2014.579.CrossRefPubMed

Myers J, Elkins T, Roberts D, Byers R. Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol Head Neck Surg. 2000;122(1):44–51. https://doi.org/10.1016/S0194-5998(00)70142-2.CrossRefPubMed

Kruse AL, Bredell M, Grätz KW. Oral squamous cell carcinoma in non-smoking and non-drinking patients. Head & Neck Oncology. 2010;2(1):24. https://doi.org/10.1186/1758-3284-2-24.CrossRef

De Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. The Lancet. 2020;2(8):180–90.

Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018 May;18(5):269–82. https://doi.org/10.1038/nrc.2018.11.CrossRefPubMed

Chow L. Head and neck Cancer. N Engl J Med. 2020;382(1):60–72. https://doi.org/10.1056/NEJMra1715715.CrossRefPubMed

Mark Welch JL, Ramírez-Puebla ST, Borisy GG. Oral microbiome geography: micron-scale habitat and niche. Cell Host Microbe. 2020;28(2):160–8. https://doi.org/10.1016/j.chom.2020.07.009.CrossRefPubMedPubMedCentral

10.

Könönen E, Gursoy M, Gursoy UK. Periodontitis: a multifaceted disease of tooth-supporting tissues. J Clin Med. 2019;8(8):1135. Published 2019 Jul 31.

11.

Hajishengallis G, Lambris JD. Complement and dysbiosis in periodontal disease. Immunobiology. 2012;217(11):1111–6. https://doi.org/10.1016/j.imbio.2012.07.007.CrossRefPubMedPubMedCentral

12.

Curtis MA, Diaz PI, Van Dyke TE. The role of the microbiota in periodontal disease. Periodontology 2000. 2020;83(1):14–25.CrossRefPubMed

13.

Elinav E, Nowarski R, Thaiss C, Hu B, Jin C, Flavell R. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2014;13(11):759–71. https://doi.org/10.1038/nrc3611.CrossRef

14.

Ye L, Jiang Y, Liu W, Tao H. Correlation between periodontal disease and oral cancer risk: a meta-analysis. J Cancer Res Ther. 2016;12(8):237–40. https://doi.org/10.4103/0973-1482.200746.CrossRef

15.

Tezal M, Sullivan MA, Hyland A, Marshall JR, Stoler D, Reid ME, et al. Chronic periodontitis and the incidence of head and neck squamous cell carcinoma. Cancer Epidemiol Biomark Prev. 2009;18(9):2406–12. https://doi.org/10.1158/1055-9965.EPI-09-0334.CrossRef

16.

Tezal M, Sullivan MA, Reid ME, Marshall JR, Hyland A, Loree T, et al. Chronic periodontitis and the risk of tongue cancer. Arch Otolaryngol Head Neck Surg. 2007;133(5):450–4. https://doi.org/10.1001/archotol.133.5.450.CrossRefPubMed

17.

Tezal M, Grossi S, Genco R. Is periodontitis associated with oral neoplasms? J Periodontol. 2005;76(3):406–10. https://doi.org/10.1902/jop.2005.76.3.406.CrossRefPubMed

18.

Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor immune microenvironment. Cell Host Microbe. 2013;14(2):207–15. https://doi.org/10.1016/j.chom.2013.07.007.CrossRefPubMedPubMedCentral

19.

Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22(2):299–306. https://doi.org/10.1101/gr.126516.111.CrossRefPubMedPubMedCentral

20.

Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17(3):156–66. https://doi.org/10.1038/s41579-018-0129-6.CrossRefPubMedPubMedCentral

21.

Kolenbrander PE, Andersen RN, Blehert DS, Egland PG, Foster JS, Palmer RJ Jr. Communication among oral bacteria. Microbiol Mol Biol Rev. 2002;66(3):486–505. https://doi.org/10.1128/MMBR.66.3.486-505.2002.CrossRefPubMedPubMedCentral

22.

Han YW, Ikegami A, Rajanna C, Kawsar HI, Zhou Y, Li M, et al. Identification and characterization of a novel adhesin unique to oral fusobacteria. J Bacteriol. 2005;187(15):5330–40. https://doi.org/10.1128/JB.187.15.5330-5340.2005.CrossRefPubMedPubMedCentral

23.

Coppenhagen-Glazer S, Sol A, Abed J, Naor R, Zhang X, Han YW, et al. Fap2 of Fusobacterium nucleatum is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth. Infect Immun. 2015;83(3):1104–13. https://doi.org/10.1128/IAI.02838-14.CrossRefPubMedPubMedCentral

24.

Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137(6):1258–68. https://doi.org/10.1002/ijc.29488.CrossRefPubMed

25.

Yu J, Chen Y, Fu X, Zhou X, Peng Y, Shi L, et al. Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway. Int J Cancer. 2016;139(6):1318–26. https://doi.org/10.1002/ijc.30168.CrossRefPubMed

26.

Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33(8):1381–90. https://doi.org/10.1007/s10096-014-2081-3.CrossRefPubMed

27.

Sun Y, An QM, Tian XY, Wang ZL, Guan XY, Dong B, et al. Fusobacterium nucleatum infection is correlated with tumor metastasis and postoperative survival of colorectal cancer patients in China. Transl Cancer Res. 2016;5(5):579–88. https://doi.org/10.21037/tcr.2016.10.45.CrossRef

28.

Yamaoka Y, Suehiro Y, Hashimoto S, Hoshida T, Fujimoto M, Watanabe M, et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol. 2018;53(4):517–24. https://doi.org/10.1007/s00535-017-1382-6.CrossRefPubMed

29.

Gethings-Behncke C, Coleman H, Jordao H, Longley D, Crawford C, Murray L, Kunzmann A. Fusobacterium nucleatum in the colorectum and its association with cancer risk and survival: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 2020; 29(3), Fusobacterium nucleatumin the Colorectum and Its Association with Cancer Risk and Survival: A Systematic Review and Meta-analysis, 29, 3, 29548, DOI: https://doi.org/10.1158/1055-9965.EPI-18-1295.

30.

Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013;66(2):462–70. https://doi.org/10.1007/s00248-013-0245-9.CrossRefPubMed

31.

Amitay EL, Werner S, Vital M, Pieper DH, Höfler D, Gierse IJ, et al. Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. Carcinogenesis. 2017;38(8):781–8. https://doi.org/10.1093/carcin/bgx053.CrossRefPubMed

32.

Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66(1):70–8. https://doi.org/10.1136/gutjnl-2015-309800.CrossRefPubMed

33.

Mitsuhashi K, Nosho K, Sukawa Y, Matsunaga Y, Ito M, Kurihara H, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget. 2015;6(9):7209–20. https://doi.org/10.18632/oncotarget.3109.CrossRefPubMedPubMedCentral

34.

Yamamura K, Baba Y, Nakagawa S, Mima K, Miyake K, Nakamura K, et al. Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res. 2016;22(22):5574–81. https://doi.org/10.1158/1078-0432.CCR-16-1786.CrossRefPubMed

35.

Yamamura K, Baba Y, Miyake K, Nakamura K, Shigaki H, Mima K, et al. Fusobacterium nucleatum in gastroenterological cancer: evaluation of measurement methods using quantitative polymerase chain reaction and a literature review. Oncol Lett. 2017;14(6):6373–8. https://doi.org/10.3892/ol.2017.7001.CrossRefPubMedPubMedCentral

36.

Hsieh YY, Tung SY, Pan HY, Yen CW, Xu HW, Lin YJ, et al. Increased abundance of Clostridium and Fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep. 2018;8(1):158. https://doi.org/10.1038/s41598-017-18596-0.CrossRefPubMedPubMedCentral

37.

Parhi L, Alon-Maimon T, Sol A, Nejman D, Shhadeh A, Fainsod-Levi T, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun. 2020;11(1):3259. https://doi.org/10.1038/s41467-020-16967-2.CrossRefPubMedPubMedCentral

38.

Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973–80. https://doi.org/10.1136/gutjnl-2015-310101.CrossRefPubMed

39.

Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548–563.e16.CrossRefPubMedPubMedCentral

40.

Wei Z, Cao S, Liu S, Yao Z, Sun T, Li Y, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. Oncotarget. 2016;7(29):46158–72. https://doi.org/10.18632/oncotarget.10064.CrossRefPubMedPubMedCentral

41.

Lee DW, Han SW, Kang JK, Bae JM, Kim HP, Won JK, et al. Association between Fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer. Ann Surg Oncol. 2018;25(11):3389–95. https://doi.org/10.1245/s10434-018-6681-5.CrossRefPubMed

42.

de Carvalho AC, de Mattos PL, Datorre JG, dos Santos W, Berardinelli GN, Matsushita MM, et al. Microbiota profile and impact of Fusobacterium nucleatum in colorectal cancer patients of Barretos cancer hospital. Front Oncol. 2019;9:813. https://doi.org/10.3389/fonc.2019.00813.CrossRefPubMedPubMedCentral

43.

Kunzmann AT, Proença MA, Jordao HW, et al. Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients. Eur J Clin Microbiol Infect Dis. 2019;38(10):1891–9. https://doi.org/10.1007/s10096-019-03649-1.CrossRefPubMedPubMedCentral

44.

Chen Y, Lu Y, Ke Y, Li Y. Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers. Medicine (Baltimore). 2019;98(39):e17221.CrossRef

45.

Yan X, Liu L, Li H, Qin H, Sun Z. Clinical significance of Fusobacterium nucleatum, epithelial–mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. OncoTargets and therapy. 2017;10:5031–46. https://doi.org/10.2147/OTT.S145949.CrossRefPubMedPubMedCentral

46.

Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358(6369):1443–8. https://doi.org/10.1126/science.aal5240.CrossRefPubMedPubMedCentral

47.

Komiya Y, Shimomura Y, Higurashi T, Sugi Y, Arimoto J, Umezawa S, et al. Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity. Gut. 2018;68(7):1335–7. https://doi.org/10.1136/gutjnl-2018-316661.CrossRefPubMed

48.

Perera M. Al-hebshi Nezar Noor, Speicher DJ, Perera I. Johnson NW Emerging role of bacteria in oral carcinogenesis: a review with special reference to perio-pathogenic bacteria Journal of Oral Microbiology. 2016;8(1):10. https://doi.org/10.3402/jom.v8.32762.

49.

Hooper SJ, Crean SJ, Lewis MAO, Spratt DA, Wade WG, Wilson MJ. Viable bacteria present within oral squamous cell carcinoma tissue. J Clin Microbiol. 2006;44(5):1719–25. https://doi.org/10.1128/JCM.44.5.1719-1725.2006.CrossRefPubMedPubMedCentral

50.

Pushalkar S, Mane SP, Ji X, Li Y, Evans C, Crasta OR, et al. Microbial diversity in saliva of oral squamous cell carcinoma. FEMS Immunol Med Microbiol. 2011;61(3):269–77. https://doi.org/10.1111/j.1574-695X.2010.00773.x.CrossRefPubMedPubMedCentral

51.

Pushalkar S, Ji X, Li Y, Estilo C, Yegnanarayana R, Singh B, et al. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiol. 2012;12(1):144. https://doi.org/10.1186/1471-2180-12-144.CrossRefPubMedPubMedCentral

52.

Schmidt BL, Kuczynski J, Bhattacharya A, Huey B, Corby PM, Queiroz EL, et al. Change in abundance of oral microbiota associated with oral cancer. PLoS One. 2014:9e98741.

53.

Nagy K, Sonkodi I, Szöke I, Nagy E, Newman H. The microflora associated with human oral carcinomas. Oral Oncol. 1998;34:304–8.CrossRefPubMed

54.

Al-Hebshi NN, Nasher AT, Idris AM, Chen T. Robust species taxonomy assignment algorithm for 16S rRNA NGS reads: application to oral carcinoma samples. Journal of Oral Microbiology. 2015;7(1):10. https://doi.org/10.3402/jom.v7.28934.CrossRefPubMedCentral

55.

Al-hebshi N, Nasher AT, Maryoud MY, Homeida HE, Chen T, Idris AM, et al. Inflammatory bacteriome featuring Fusobacterium nucleatum and Pseudomonas aeruginosa identified in association with oral squamous cell carcinoma. Sci Rep. 2017;7(1):1834. https://doi.org/10.1038/s41598-017-02079-3.CrossRefPubMedPubMedCentral

56.

Zhang L, Liu Y, Zheng HJ, Zhang CP. The oral microbiota may have influence on oralc. Front Cell Infect Microbiol. 2020;9:476. https://doi.org/10.3389/fcimb.2019.00476.CrossRefPubMedPubMedCentral

57.

Zhao H, Chu M, Huang Z, Yang X, Ran S, Hu B, et al. Variations in oral microbiota associated with oral cancer. Sci Rep. 2017;7(1):11773. https://doi.org/10.1038/s41598-017-11779-9.CrossRefPubMedPubMedCentral

58.

Guerrero-Preston R, White JR, Godoy-Vitorino F, Rodríguez-Hilario A, Navarro K, González H, et al. High-resolution microbiome profiling uncovers Fusobacterium nucleatum, lactobacillus gasseri/johnsonii, and lactobacillus vaginalis associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation. Oncotarget. 2017;8(67):110931–48. https://doi.org/10.18632/oncotarget.20677.CrossRefPubMedPubMedCentral

59.

Perera M, Al-hebshi NN, Perera I, Ipe D, Ulett GC, Speicher DJ, et al. Inflammatory Bacteriome and Oral squamous cell carcinoma. J Dent Res. 2018;97(6):725–32. https://doi.org/10.1177/0022034518767118.CrossRefPubMed

60.

Hsiao JR, Chang CC, Lee WT, Huang CC, Ou CY, Tsai ST, et al. The interplay between oral microbiome, lifestyle factors and genetic polymorphisms in the risk of oral squamous cell carcinoma. Carcinogenesis. 2018;39(6):778–87. https://doi.org/10.1093/carcin/bgy053.CrossRefPubMed

61.

Chang C, Geng F, Shi X, Li Y, Zhang X, Zhao X, et al. The prevalence rate of periodontal pathogens and its association with oral squamous cell carcinoma. Appl Microbiol Biotechnol. 2018;103(3):1393–404. https://doi.org/10.1007/s00253-018-9475-6. [Epub ahead of print].CrossRefPubMed

62.

Yost S, Stashenko P, Choi Y, Kukuruzinska M, Genco CA, Salama A, et al. Increased virulence of the oral microbiome in oral squamous cell carcinoma revealed by metatranscriptome analyses. Int J Oral Sci. 2018;10(4):32. https://doi.org/10.1038/s41368-018-0037-7.CrossRefPubMedPubMedCentral

63.

Bronzatoa JD, Bomfim RA, Edwards DH, Crouch D, Hector MP, et al. Detection of Fusobacterium in oral and head and neck cancer samples: a systematic review and meta-analysis. Arch Oral Biol. 2020;112:104669. https://doi.org/10.1016/j.archoralbio.2020.104669.CrossRef

64.

Amer A, Galvin S, Healy CM, Moran GP. The microbiome of potentially malignant oral leukoplakia exhibits enrichment for Fusobacterium, Leptotrichia, Campylobacter, and Rothia species. Front Microbiol. 2017;8:2391. https://doi.org/10.3389/fmicb.2017.02391.CrossRefPubMedPubMedCentral

65.

Decsi G, Soki J, Pap B, Dobra G, Harmati M, Kormondi S, et al. Chicken or the egg: microbial alterations in biopsy samples of patients with oral potentially malignant disorders. Pathol Oncol Res. 2019;25(3):1023–33. https://doi.org/10.1007/s12253-018-0457-x.CrossRefPubMed

66.

Neuzillet C, Marchais M, Vacher S, Hilmi M, Schnitzler A, Meseure D, et al. Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients. Sci Rep. 2021;11(1):7870. https://doi.org/10.1038/s41598-021-86816-9.CrossRefPubMedPubMedCentral

67.

Chen Z, Wong PY, Ng CWK, Lan L, Fung S, Li JW, et al. The intersection between oral microbiota, host gene methylation and patient outcomes in head and neck squamous cell carcinoma. Cancers. 2020;12(11):3425. https://doi.org/10.3390/cancers12113425.CrossRefPubMedCentral

68.

Gallimidi AB, Fischman S, Revach B, Bulvik R, Maliutina A, Rubinstein AM, et al. Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model. Oncotarget. 2015;6(26):22613–23. https://doi.org/10.18632/oncotarget.4209.CrossRefPubMedCentral

69.

Harrandah A, Chukkapalli S, Bhattacharyya I, Progulske-Fox A, Chan E. Fusobacteria modulate oral carcinogenesis and promote cancer progression. J Oral Microbiology. 2020;31(1):1849493. https://doi.org/10.1080/20002297.2020.1849493.CrossRef

70.

Abed J, Emgård JEM, Zamir G, Faroja M, Almogy G, Grenov A, et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed gal-GalNAc. Cell Host Microbe. 2016;20(2):215–25. https://doi.org/10.1016/j.chom.2016.07.006.CrossRefPubMedPubMedCentral

71.

Abed J, Maalouf N, Parhi L, Chaushu S, Mandelboim O, Bachrach G. Tumor targeting by Fusobacterium nucleatum: a pilot study and future perspectives. Frontiers in Cellular and Infectious Microbiology. 2017;7:295. https://doi.org/10.3389/fcimb.2017.00295.CrossRef

72.

Mazumdar S, SenGupta SK, Param R, Sinha SN. Binding pattern of eight different lectins in healthy subjects and patients with dysplastic and malignant lesions of the oral cavity. Int J Oral Maxillofac Surg. 1993;22(5):301–5. https://doi.org/10.1016/S0901-5027(05)80521-1.CrossRefPubMed

73.

Huang R, Li M, Gregory RL. Bacterial interactions in dental biofilm. Virulence. 2011;2(5):435–44. https://doi.org/10.4161/viru.2.5.16140.CrossRefPubMedPubMedCentral

74.

Katz J, Onate MD, Pauley KM, Bhattacharyya I, Cha S. Presence of Porphyromonas gingivalis in gingival squamous cell carcinoma. International Journal of Oral Science. 2011;3(4):209–15. https://doi.org/10.4248/IJOS11075.CrossRefPubMedPubMedCentral

75.

Olsen I, Yilmaz Ö. Possible role of Porphyromonas gingivalis in orodigestive cancers. J Oral Microbiol. 2019;11(1):1563410. https://doi.org/10.1080/20002297.2018.1563410.CrossRefPubMedPubMedCentral

76.

Alnuaimia AD, Wiesenfeld D, O’Brien-Simpson NM, Reynolds EC, McCullough MJ. Oral Candida colonization in oral cancer patients and its relationship with traditional risk factors of oral cancer: a matched case-control study. Oral Oncol. 2015;51(1):139–45. https://doi.org/10.1016/j.oraloncology.2014.11.008.CrossRef

77.

Bor B, Cen L, Agnello M, Shi W, He X. Morphological and physiological changes induced by contact-dependent interaction between Candida albicans and Fusobacterium nucleatum. Sci Rep. 2016;6(1):27956. https://doi.org/10.1038/srep27956.CrossRefPubMedPubMedCentral

78.

Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signalling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195–206. https://doi.org/10.1016/j.chom.2013.07.012.CrossRefPubMedPubMedCentral

79.

Ma C-T, Luo H-S, Gao F, Tang Q-C, Chen W. Fusobacterium nucleatum promotes the progression of colorectal cancer by interacting with E-cadherin. Oncol Lett. 2018;16(2):2606–12. https://doi.org/10.3892/ol.2018.8947.CrossRefPubMedPubMedCentral

80.

Fardini Y, Wang X, Témoin S, Nithianantham S, Lee D, Shoham M, et al. Fusobacterium nucleatum adhesin FadA binds vascular-endothelial cadherin and alters endothelial integrity. Mol Microbiol. 2011;82(6):1468–80. https://doi.org/10.1111/j.1365-2958.2011.07905.x.CrossRefPubMedPubMedCentral

81.

Rubinstein MR, Baik JE, Lagana SM, et al. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep. 2019;20(4):e47638.CrossRefPubMedPubMedCentral

82.

Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signalling to nuclear factor-κB, and up-regulating expression of MicroRNA-21. Gastroenterology. 2017;152(4):851–66.CrossRefPubMed

83.

Wu Y, Wu J, Chen T, Li Q, Peng W, Li H, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis in mice via a toll-like receptor 4/p21-activated kinase 1 cascade. Dig Dis Sci. 2018;63(5):1210–8. https://doi.org/10.1007/s10620-018-4999-2.CrossRefPubMed

84.

Geng F, Zhang Y, Lu A, Zhang S, Pan Y. Fusobacterium nucleatum caused DNA damage and promoted cell proliferation by the Ku70/p53 pathway in oral cancer cells. DNA and Cell Biology. 2020;39(1).

85.

Kang W, Jia Z, Tang D, Zhang Z, Gao H, He K, et al. Fusobacterium nucleatum facilitates apoptosis, ROS generation, and inflammatory cytokine production by activating AKT/MAPK and NF-κB signaling pathways in human gingival fibroblasts. Oxidative Med Cell Longev. 2019;2019:1681972–22. https://doi.org/10.1155/2019/1681972.CrossRef

86.

Tang B, Wang K, Jia YP, Zhu P, Fang Y, Zhang ZJ, et al. Fusobacterium nucleatum-induced impairment of autophagic flux enhances the expression of proinflammatory cytokines via ROS in Caco-2 cells. PLoS One. 2016;11(11):e0165701. https://doi.org/10.1371/journal.pone.0165701.CrossRefPubMedPubMedCentral

87.

Guijarro-Muñoz I, Compte M, Álvarez-Cienfuegos A, Álvarez-Vallina L, Sanz L. Lipopolysaccharide activates toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway and proinflammatory response in human pericytes. J Biol Chem. 2014;289(4):2457–68. https://doi.org/10.1074/jbc.M113.521161.CrossRefPubMed

88.

Zu Y, Ping W, Deng T, Zhang N, Fu X, Sun W. Lipopolysaccharide-induced toll-like receptor 4 signaling in esophageal squamous cell carcinoma promotes tumor proliferation and regulates inflammatory cytokines expression. Dis Esophagus. 2017;30(2):1–8. https://doi.org/10.1111/dote.12466.CrossRefPubMed

89.

Quah SY, Bergenholtz G, Tan KS. Fusobacterium nucleatum induces cytokine production through toll-like-receptor-independent mechanism. Int Endod J. 2013;47(6):550–9. https://doi.org/10.1111/iej.12185.CrossRefPubMed

90.

Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, et al. Fusobacterium nucleatum and T-cells in colorectal carcinoma. JAMA oncology. 2015;1(5):653–61. https://doi.org/10.1001/jamaoncol.2015.1377.CrossRefPubMedPubMedCentral

91.

Chen T, Li Q, Zhang X, Long R, Wu Y, Wu J, et al. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection. Hum Pathol. 2018;79:93–101. https://doi.org/10.1016/j.humpath.2018.05.008.CrossRefPubMed

92.

Shenker BJ, Datar S. Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle. Infect Immun. 1995;63(12):4830–6. https://doi.org/10.1128/iai.63.12.4830-4836.1995.CrossRefPubMedPubMedCentral

93.

Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–55. https://doi.org/10.1016/j.immuni.2015.01.010.CrossRefPubMedPubMedCentral

94.

Kaplan CW, Ma X, Paranjpe A, et al. Fusobacterium nucleatum outer membrane proteins Fap2 and RadD induce cell death in human lymphocytes. Infect Immun. 2010;78(11):4773–8.CrossRefPubMedPubMedCentral

95.

Chen T, Li Q, Wu J, Wu Y, Peng W, Li H, et al. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism. Cancer Immunol Immunother. 2018 Oct;67(10):1635–46. https://doi.org/10.1007/s00262-018-2233-x.CrossRefPubMed

96.

Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67. https://doi.org/10.1016/j.cell.2010.03.015.CrossRefPubMedPubMedCentral

97.

Uitto V-J, Baillie D, Wu Q, Gendron R, Grenier D, Putnins EE, et al. Fusobacterium nucleatum increases collagenase 3 production and migration of epithelial cells. Infect Immun. 2005;73(2):1171–9. https://doi.org/10.1128/IAI.73.2.1171-1179.2005.CrossRefPubMedPubMedCentral

98.

Inaba H, Sugita H, Kuboniwa M, Iwai S, Hamada M, Noda T, et al. Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation. Cell Microbiol. 2014;16(1):131–45. https://doi.org/10.1111/cmi.12211.CrossRefPubMed

99.

Inaba H, Amano A, Lamont RJ, Murakami Y. Involvement of protease-activated receptor 4 in over-expression of matrix metalloproteinase 9 induced by Porphyromonas gingivalis. Med Microbiol Immunol. 2015;204(5):605–12. https://doi.org/10.1007/s00430-015-0389-y.CrossRefPubMed

100.

Ha NH, Woo BH, Kim da J, Ha ES, Choi JI, Kim SJ, et al. Prolonged and repetitive exposure to Porphyromonas gingivalis increases aggressiveness of oral cancer cells by promoting acquisition of cancer stem cell properties. Tumour Biol 2015;36:9947–9960, 12, DOI: https://doi.org/10.1007/s13277-015-3764-9.

101.

Krisanaprakornkit S, Iamaroon A. Epithelial-mesenchymal transition in Oral squamous cell carcinoma. ISRN Oncol. 2012;2012:681469–10. https://doi.org/10.5402/2012/681469.CrossRefPubMedPubMedCentral

102.

Their JP. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer. 2002;2(6):442–54. https://doi.org/10.1038/nrc822.CrossRef

103.

Abdulkareem AA, Shelton RM, Landini G, Cooper PR, Milward MR. Periodontal pathogens promote epithelial-mesenchymal transition in oral squamous carcinoma cells in vitro. Cell Adhes Migr. 2018;12(2):127–37. https://doi.org/10.1080/19336918.2017.1322253.CrossRef

104.

Zhang S, Li C, Liu J, Geng F, Shi X, Li Q, et al. Fusobacterium nucleatum promotes epithelial-mesenchymal transition through regulation of the lncRNA MIR4435-2HG/miR-296-5p/Akt2/SNAI1 signaling pathway. FEBS J. 2020;287(18):4032–47. https://doi.org/10.1111/febs.15233.

105.

Baud J, Varon C, Chabas S, Chambonnier L, Darfeuille F, Staedel C. Helicobacter pylori initiates a mesenchymal transition through ZEB1 in gastric epithelial cells. PLoS One. 2013;8(4):e60315. https://doi.org/10.1371/journal.pone.0060315.

106.

Kamarajan P, Ateia I, Shin JM, Fenno JC, le C, Zhan L, et al. Periodontal pathogens promote cancer aggressivity via TLR/MyD88 triggered activation of integrin/FAK signaling that is therapeutically reversible by a probiotic bacteriocin. PLoS Pathog. 2020;16(10):e1008881. https://doi.org/10.1371/journal.ppat.1008881.CrossRefPubMedPubMedCentral

107.

Nguyen T, Brody H, Lin GH, Range H, Kuraji R, Ye C, et al. Probiotics, including nisin-based probiotics, improve clinical and microbial outcomes relevant to oral and systemic diseases. Periodontol 2000. 2020;82(1):173–185.

108.

Liu PF, Shi W, Zhu W, Smith JW, Hsieh SL, Gallo RL, et al. Vaccination targeting surface FomA of Fusobacterium nucleatum against bacterial co-aggregation: implication for treatment of periodontal infection and halitosis. Vaccine. 2010;28(19):3496–505. https://doi.org/10.1016/j.vaccine.2010.02.047.CrossRefPubMedPubMedCentral

109.

Guo SH, Wang HF, Nian ZG, Wang YD, Zeng QY, Zhang G. Immunization with alkyl hydroperoxide reductase subunit C reduces Fusobacterium nucleatum load in the intestinal tract. Sci Rep. 2017;7(1):10566. https://doi.org/10.1038/s41598-017-11127-x.CrossRefPubMedPubMedCentral

110.

Gopinath D, Wie CC, Banerjee M, Thangavelu L, Kumar R P, Nallaswamy D, et al. Compositional profile of mucosal bacteriome of smokers and smokeless tobacco users. Clin Oral Invest. 2021. https://doi.org/10.1007/s00784-021-04137-7.

111.

Fulbright LE, Ellermann M, Arthur JC. The microbiome and the hallmarks of cancer. PLoS Pathog. 2017;13(9):e1006480. https://doi.org/10.1371/journal.ppat.1006480.CrossRefPubMedPubMedCentral

Title: Fusobacterium nucleatum and oral cancer: a critical review
Authors: Emily McIlvanna
Gerard J. Linden
Stephanie G. Craig
Fionnuala T. Lundy
Jacqueline A. James
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Oral Cancer
Oral Cavity Carcinoma
Colorectal Cancer
Colorectal Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08903-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens

Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review

The effects of physical activity on overall survival among advanced cancer patients: a systematic review and meta-analysis

Effect of d-limonene and its derivatives on breast cancer in human trials: a scoping review and narrative synthesis

Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation

High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer